Morningstar

Arrowhead Pharmaceuticals Inc ARWR

Morningstar Rating

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Business Wire Sep 23, 2024 11:30am
Arrowhead Pharmaceuticals Gets FDA Breakthrough Designation for Plozasiran

Global News Select Sep 10, 2024 11:59am
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran

Business Wire Sep 10, 2024 11:30am
Arrowhead Pharmaceuticals Shares Climb on Plans to File New Drug Application for Plozasiran

Global News Select Sep 3, 2024 10:38am
Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Business Wire Sep 2, 2024 10:36am
Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Business Wire Aug 21, 2024 11:30am
Arrowhead Pharmaceuticals to Advance Two Treatments for Obesity, Metabolic Diseases

Global News Select Aug 14, 2024 6:05pm
Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies

Business Wire Aug 14, 2024 5:30pm
Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results

Business Wire Aug 8, 2024 8:01pm
Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street

Business Wire Aug 8, 2024 8:00pm
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Business Wire Jul 29, 2024 8:30pm
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results

Business Wire Jul 24, 2024 11:30am

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2024 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.